Financial Performance - Revenue for the year ending December 31, 2025, was $174,000, a decrease of 97.9% compared to $8,131,000 for the year ending December 31, 2024[3]. - The company reported a net loss of $17,875,000 for the year ending December 31, 2025, which is an increase of 16.8% from a net loss of $15,303,000 in the previous year[3]. - The cost of sales for 2025 was $1,091,000, down from $1,992,000 in 2024, resulting in a gross loss of $917,000[17]. - The company reported a total comprehensive loss of $16,605,000 in 2025, slightly higher than the $16,129,000 reported in 2024[18]. - The company's revenue for 2025 was $174,000, a significant decrease from $8,131,000 in 2024, primarily due to customer returns totaling $5,893,000[26]. - The company incurred a loss of $17,875,000 in 2025, compared to a loss of $15,303,000 in 2024[44]. - The company reported a basic loss per share of $0.0370 for 2025, based on a weighted average of 483,759,463 shares outstanding[43]. - The adjusted net loss for the year ended December 31, 2025, was $(16.9) million, compared to $(15.1) million in 2024[112]. Product Development and Approvals - The core product BroncAblate® received approval from the NMPA for commercialization in China, marking a significant advancement in lung cancer treatment technology[4]. - InterVapor® has been successfully launched in nearly 30 provinces/cities in China, demonstrating effective treatment for severe COPD[5]. - As of December 31, 2025, BroncAblate® has been applied in over 200 surgeries across more than 30 hospitals in China[6]. - The company holds 94 registration certificates as of December 31, 2025, including 20 NMPA certificates, 4 CE certificates, and 7 FDA certificates[14]. - Clinical trials for BroncTarget® are ongoing, with 116 subjects enrolled across 28 hospitals as of December 31, 2025[9]. - The company has developed a comprehensive interventional respiratory disease treatment platform, integrating navigation, diagnosis, and treatment[52]. - BroncTarget® is the first domestically developed targeted radiofrequency ablation system in China, currently undergoing confirmatory clinical trials[63]. - The BroncAblate® system has been approved for use in over 30 hospitals, completing nearly 200 procedures as of December 31, 2025[61]. - InterVapor® has received CE and NMPA certifications, allowing commercialization in multiple regions including Europe, China, and Australia[65]. Strategic Partnerships and Market Expansion - The company is pursuing strategic partnerships and industry acquisitions to explore further development potential[13]. - The company entered into a share subscription agreement with Shanghai Yingtai Medical Co., Ltd. and Hangzhou Linping National Capital Investment Co., Ltd. to enhance product commercialization channels[15]. - The acquisition of 157,800 shares of Valgen Holding Corporation aims to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases[15]. - The company has designated Customer A as the exclusive domestic distributor for its medical devices in China, aiming to strengthen market presence amid regulatory changes[26]. - The company is committed to deepening its partnership with Customer A, leveraging their strong distribution capabilities in Chinese hospitals[26]. - The company is expanding its market presence, with BroncAblate® achieving listing approval in Hong Kong and ongoing registrations in other countries[62]. Research and Development - The company’s R&D expenses decreased to $7,772,000 in 2025 from $11,471,000 in 2024, a reduction of 32.5%[17]. - Research and development costs for 2025 were $7,772,000, down from $11,471,000 in 2024, indicating a strategic shift in R&D investment[33]. - Employee costs accounted for 47.9% of total R&D expenses in 2025, down from 49.5% in 2024, totaling $3.7 million[102]. Operational Metrics - Total assets less current liabilities decreased to $150,209,000 in 2025 from $169,477,000 in 2024, a decline of 11.4%[20]. - The company’s cash and cash equivalents decreased to $31,697,000 in 2025 from $46,473,000 in 2024, a decline of 31.8%[19]. - The total trade receivables decreased to $6,083,000 in 2025 from $10,344,000 in 2024, with a net amount of $3,180,000 after impairment[46]. - The company has maintained a total of 191 employees, with 170 based in China and 21 overseas[125]. Awards and Recognition - The company received multiple industry awards in 2025, enhancing its brand recognition and influence in the minimally invasive treatment of pulmonary diseases[16]. - The BRONC-RFII study results were published in the journal Respirology, highlighting the safety and efficacy of the BroncAblate® system[59]. - InterVapor® has been recognized as a "Breakthrough Device" by the FDA and is included in the GOLD guidelines for COPD treatment[64]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance codes during the reporting period, with one exception regarding the separation of the roles of Chairman and CEO[118]. - The audit committee reviewed the annual consolidated financial statements and found them compliant with applicable accounting standards and regulations[126]. - There were no significant lawsuits or arbitrations involving the company during the reporting period[124]. Future Plans and Projections - The expected revenue to be recognized from remaining performance obligations is $821,000 for 2025, an increase from $586,000 in 2024[32]. - The company plans to allocate HKD 194.0 million for mergers, investments, or acquisitions of new product lines, with full utilization expected by 2030[137]. - The company plans to hold its annual general meeting on May 14, 2026[139].
堃博医疗(02216) - 2025 - 年度业绩